How a Device Startup Wins Its First Hospital (Illustrative Case Study)
Case StudiesA fictional device company has a cleared dressing, one surgeon champion and no buying path. An illustrative twelve-week plan to win one named hospital, with claims, evidence and price that committee will ask for.
In this article
- Snapshot
- The situation
- Phase 1: Diagnose (weeks 1 and 2)
- Phase 2: Design (weeks 3 to 6)
- Phase 3: Execute (weeks 7 to 12)
- Projected results, 12 months after launch
- What has to go right
- What carries over to any device company
- Method and limits
- Questions founders ask
- Related on AAJ
- References
Share
Ask AAJ about this articleExample Co. is a fictional medical device company, and this is an illustrative sample engagement: the numbers are modelled projections, not client results. It shows how AAJ would approach a problem many device founders have, a cleared product, one enthusiastic surgeon and a supply chain office that never replies.
In my view, a small device company should not try to “sell to the hospital”. It should win one named committee at one named hospital, with the claims, evidence and price that committee will ask for, and write down how long each step took. In this example the plan targets a 300-bed community hospital in a six-hospital system, because a win there is also the first step into the other five.
Key figures
84.1% of 4,760 hospitals were served by three group purchasing organizations in 2024 $45,600 a year from the first hospital, in the model 10 sites needed to reach about $456,000 a year at that sizeSnapshot
Example Co. and the hospitals are fictional; the figures are modelled projections, not client results.
The situation
Example Co. had a 510(k)-cleared dressing, a surgeon at a community hospital who liked it, and a list of supply chain directors who had not answered its cold emails. The team of 11 was working on five kinds of buyer at once. It could not say which contract covered the dressing at its champion’s hospital, who would decide, what that group would ask for, or when.
Illustrative. Example Co. and the hospitals are fictional; the figures are modelled projections, not client results.
Phase 1: Diagnose (weeks 1 and 2)
The aim is to find out how this one hospital buys, from the people who do the buying.
- Which contract. Ask the champion and the materials management office which group purchasing organization the hospital uses for dressings, and which distributor delivers. A 2026 research letter in JAMA Health Forum found that, in 2024, three group purchasing organizations covered 84.1 percent of 4,760 hospitals, so the answer is usually one of a few names, but the hospital has to confirm it1. GAO’s 2014 report quotes a trade association estimate that about 96 to 98 percent of U.S. hospitals buy through such contracts2. A group contract is a route to the hospital, not an order for the product.
- Who decides. The surgeon is the champion, not the decision-maker. Map the value analysis committee, the perioperative nurse leader, infection prevention and supply chain, and note who the system, not the hospital, controls.
- What the hospital uses now. The incumbent dressing, its unit price and the volume of closures a year. Without these the value case is a guess.
- How long it takes. No public source gives a typical committee cycle, so the plan records the real dates from the first conversation.
Diagnosis: the product was not the problem. The team did not know the buying path at one site, so it could not prepare what that site would ask for.
Phase 2: Design (weeks 3 to 6)
The aim is to prepare the claims, the evidence and the offer before anyone asks.
- Claims that match the clearance. The FDA decides a device’s intended use from labeling, advertising and the statements of the company and its representatives, not only from the clearance letter3. The website, deck and sales team are checked against the cleared indication, and the status is written as “FDA cleared”, since clearance is not approval4.
- A short evidence plan. Bench data and the surgeon’s own case series are labelled as what they are. A comparative study is costed before it is promised, because the committee will ask whether the dressing lowers dressing changes, dehiscence or time in the operating room, and a claim of that kind needs substantiation.
- A value analysis pack. One page on the problem, the clearance, the evidence, the unit price against the incumbent and what the hospital would measure in a trial. The hospital’s own numbers go in the comparison.
- An evaluation agreement. A 60-day trial in the operating room with a stated unit price, a named owner, the measures agreed in advance and a decision date.
Phase 3: Execute (weeks 7 to 12)
The aim is to take one hospital from trial to a standing order, and record the dates.
- Weeks 7 and 8 Submit the value analysis pack through the committee’s own route Agree the 60-day trial, measures and decision date in writing
- Weeks 9 to 11 Trial runs in the operating room with a named owner Record the dates of every step
- Week 12 Readout against the agreed measures Request for the standing order, and a first conversation with the system
Illustrative plan. Example Co. and the hospitals are fictional; the figures are modelled projections, not client results.
The dressing is a low-cost, single-use item, so the hospital’s question is less whether it can afford the dressing than what it has to change and who answers if something goes wrong. In my view the pack should answer that second question first.
AAJ resources used: the MedTech Marketing Playbook (Steps 2, 3, 5, 8 and 9), the MedTech Claims Checker, the Value Analysis Pack Template and the Evaluation Agreement Template.
Projected results, 12 months after launch
Projections, not historical results. Example Co. and the hospitals are fictional; the figures are modelled projections, not client results.
These are projections, not historical results. They use a price of $38 a dressing and an assumed 1,200 closures a year at the first hospital, so the first site is worth $45,600 a year. If all six hospitals adopted at a similar rate the total would be about $273,600 a year. On a real project the volumes would come from the hospital’s own records.
What has to go right
This is AAJ’s arithmetic on the example. The first hospital’s $45,600 a year is 1,200 × $38. The company needs about 10 such sites to reach the goal of ten approved hospitals, and at that size they would bring in about $456,000 a year, which would not fund a team of 11. In my view that is the real finding: at $38 a unit the plan works only if the six-hospital system adopts together, or if the clinic reorders and the price move the total up. A one-site win is a proof point, not a business.
What carries over to any device company
- Win one named committee first. Learn the buying path at one site, and the next site is faster.
- Keep claims inside the clearance. The website and the sales deck are part of the intended use.
- Bring the hospital’s numbers. The value case is the hospital’s unit price and volume, not yours.
- Write down the dates. No public source tells you how long a committee takes; your own record will.
Method and limits
Example Co. is fictional and every figure about it is illustrative; $38 a dressing, 1,200 closures a year and a six-hospital system are assumptions. The outside sources describe the market and the rules in general; none shows what a particular hospital will do. This is general information, not legal or regulatory advice.
Questions founders ask
Why do device startups stall with hospitals?In this illustrative example the team did not know which contract covered its product, who decided, or what the incumbent cost, so it could not prepare what the committee would ask for.
How long does a hospital value analysis committee take?No public source gives a reliable figure, so the plan records its own request, decision, contract and first-order dates at each hospital.
Can a device company say its product is FDA approved?Not if it was cleared. Under 21 CFR 807.97, clearance does not denote approval, so the plan writes the status as FDA cleared.
Is this a real client result?No. Example Co. is fictional and every figure is a modelled projection.
Related on AAJ
Playbooks
References
The superscript numbers in the article match this list.
All four sources were opened on October 22, 2026.
- JAMA Health Forum (2026). Research letter on hospital group purchasing organization affiliation, 2014 and 2024. jamanetwork.com
- U.S. Government Accountability Office (2014). Group Purchasing Organizations, GAO-15-13. gao.gov
- eCFR. 21 CFR 801.4, Meaning of intended uses. ecfr.gov
- eCFR. 21 CFR 807.97, Misbranding by reference to premarket notification. ecfr.gov
Written by Saroj Jha
Founder of AAJ
Saroj has spent more than ten years in marketing strategy. He writes AAJ’s articles in his own voice, and every figure in them is referenced.
The AAJ monthly brief
One email a month with the newest articles and research
New articles, playbooks and studies, with every source listed. Unsubscribe any time.
Work email